Clinical Trial Update: A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants [Phase 3]

View source ↗

Summary

This update reports completion of a Phase 3 study evaluating the safety and effectiveness of HAC 22L Injection for mid-face volume in adults with facial volume …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facial Volume Deficit

Drugs mentioned

• HAC 22L Injection

Snippet

Sponsor: AbbVie | Conditions: Facial Volume Deficit | Phase 3 | Status: COMPLETED